Drug major Cipla Friday announced the launch of its proprietary respiratory inhalation
therapy product ‘Niveoli’ in India. Niveoli is used in respiratory inhalation therapy that addresses an
unmet need associated with obstructive airway diseases (OAD) such as asthma and chronic
obstructive pulmonary disorder (COPD), Cipla said in a BSE filing. Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow.The main symptoms include shortness of breath and cough with sputum production.
The company said Niveoli, extra-fine particle beclomethasone-formoterol combination hydrofluoroalkane (HFA) inhaler for adults, targets drug delivery to the small airways.
“We see our market leadership, as well as the range and depth of our R&D and manufacturing capabilities in this therapy as a privilege and a responsibility to do more for patients,” Cipla Head – India business Nikhil Chopra said.
Cipla Limited is a multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India. The company primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions. – Business Medical Dialogues